1 Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the

- 2 Central African Republic
- 3

4 Viral hepatitis and HIV co-infection in the Central African Republic

- 5
- Parvine Basimane-Bisimwa^{1,2,3,4}, Giscard Wilfried Koyaweda¹, Edgarthe Ngaïganam¹, Ulrich
 Vickos⁵, Ornella Anne Demi Sibiro¹, Brice Martial Yambiyo⁶, Benjamin Seydou Sombié⁷, Pulchérie
 Pélembi⁸, Sandrine Moussa⁸, Claudine Bekondi⁹, Tamara Giles-Vernick¹⁰, Alexandre Manirakiza⁶,
 Muriel Vray¹¹, Narcisse Patrice Joseph Komas^{1*}
- 10

¹Viral hepatitis laboratory, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic

¹² ²Université Evangélique en Afrique (UEA), Bukavu, Democratic Republic of Congo.

³International Center Advanced for Research and Training (ICART), Bukavu, Democratic Republic of

14 Congo.

⁴Hôpital Général de Référence de Panzi, Bukavu, Democratic Republic of Congo.

⁵Laboratory of arbovirus, haemorrhagic fevers, emerging virus and zoonosis, Institut Pasteur de

17 Bangui, PO Box 923, Bangui, Central African Republic

18 ⁶Epidemiology service, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African Republic

19 ⁷Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Burkina Faso

20 ⁸Service des Retrovirus-VIH, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African

21 Republic.

⁹Centre de Ressources Biologiques, Institut Pasteur de Bangui, PO Box 923, Bangui, Central African
Republic

- ²⁴ ¹⁰Anthropology & Ecology of Disease Emergence Unit, Institut Pasteur, Paris
- ²⁵ ¹¹Unit of epidemiology of emergent infections, Institut Pasteur, INSERM, Paris.
- 26 *Converspondischingera retrievers newplesearchentary as noo been perilies by been reviewand should the bebeused of and Pathical practice.

27

28 [¶]These authors contributed equally to this work

30 Abstract

Background: The Central African Republic (CAR) is one of the countries with the highest prevalence
of viral hepatitis infection in the world. The present study describes the geographic distribution of viral
hepatitis infections and molecular characterization of these viruses in the CAR.

Methodology: Out of 12,599 persons enrolled during the 4th Multiple Indicator Cluster Survey of 2010 in the CAR, 10,621 Dried Blood Spot (DBS) samples were obtained and stored at -20°C. Of these DBS, 4,317 samples were randomly selected to represent all regions of the CAR. Serological tests for hepatitis B, D, and C viruses were performed using the ELISA technique. Molecular characterization was performed to identify strains.

Results: Of the 4,317 samples included, 53.2% were males and 46.8% females. The HBsAg prevalence among participants was 12.9% and that HBc-Ab was 19.7%. The overall prevalence of the HCV was 0.6%. Co-infection of HIV/HBV was 1.41% and that of HBV/HDV was 16.6%. A total of 77 HBV, 6 HIV, and 6 HDV isolates were successfully sequenced, with 72 HBV (93.5%) strains belonging to genotype E and 5 (6.5%) isolates belonging to genotype D. The 6 HDV isolates all belonged to clade 1, while 4 recombinants sub-type were identified among the 6 isolates of HIV.

45 Conclusion: Our study found a high prevalence of HBV, HBV/HDV and HBV/HIV co-infection, but
46 a low prevalence of HCV. CAR is still in an area of high HBV endemicity. This study's data and
47 analyses would be useful for establishing an integrated viral hepatitis and HIV surveillance program in
48 the CAR.

49

50 Keywords: HBV; HCV; HBV-HDV co-infection; HIV-HBV coinfections; Prevalence; HBV/HDV
51 Molecular characterization; Hepatitis B virus; Hepatitis C virus; Hepatitis D virus; CAR.

52 Introduction

Hepatitis is defined as an inflammation of the liver. It can be self-limiting or in some cases, progress to fibrosis (scarring), cirrhosis, or liver cancer. Hepatitis may be caused by toxins, certain drugs, heavy alcohol use, and bacterial and viral infections. Hepatitis viruses are the most common cause of hepatitis in the world [1].

57 There are 5 main hepatitis viruses, referred to as types A, B, C, D, and E. Each type of hepatitis is 58 caused by a different virus, is spread differently, and accounts for variable prevalence and mortality 59 around the world [1]. Globally, viral hepatitis infection is a major public health problem. Each year, 60 1.4 million people die from viral hepatitis-related cirrhosis and liver cancer [2]. Prevalence varies 61 according to geographical area. Following Asia, Africa has the second largest number of chronic 62 HBV carriers and is considered to be a region of high endemicity [3]. In 2015, the number of deaths 63 caused by hepatitis viruses resembled the number of deaths caused by tuberculosis and higher than 64 those caused by HIV [4]. Viral hepatitis mortality has been increasing over time, whereas 65 tuberculosis and HIV mortality has declined. In most cases, mortality due to viral hepatitis in 2015 66 was caused by chronic liver disease and primary liver cancer, causing some 720,000 and 470,000 67 deaths respectively [4]. The HCV epidemic affects all regions of the world, with major differences 68 between and within countries [4]. The HDV, a satellite RNA-virus depending on HBV for its 69 propagation. Both HBV and HDV occur worldwide, with an estimated 240 million people 70 worldwide chronically infected with HBV [4,5], of whom approximately 15 to 20 million, or 5% 71 are co-infected with HDV [6]. In combination with HBV, HDV causes the most severe form of 72 viral hepatitis in humans, including fulminant hepatitis and hepatocellular failure, with rapid 73 progression to hepatic cirrhosis followed by hepatic decompensation, and an increased risk of 74 hepatocellular carcinoma [7-9]. Additionally, HBV/HIV coinfection increases the morbidity and mortality beyond the cause of mono-infection by either one of those viruses. HBV patients 75 76 coinfected with HIV have higher levels of hepatitis B viremia, have progression to chronic hepatitis

77 B that is approximately five times as fast as that among people infected with only HBV, and have a

78 higher risk of cirrhosis and hepatocellular carcinoma[10].

Although Africa has very high HBV endemicity, HDV prevalence remains poorly known and is thus
increasingly studied [4]. Nevertheless, in Africa, of the estimated 65 million chronic HBV carriers,

81 about one-fourth of HBsAg-positive individuals show dual-infection with HDV. Thus, Central Africa

has an overall prevalence of 25.6%, West Africa 7.3%, and East and South Africa 0.05% [11].

Numerous seroprevalence studies of viral hepatitis have been conducted in CAR between 1984 and the present day, most focusing on the capital Bangui and its suburbs [12,13]. Although national studies to evaluate national prevalence of HIV (3.5%) [14] and HIV/HBV coinfection have been conducted, in addition to Bangui-centered studies of HBV/HDV [11,15], no studies to date have estimated CAR's HBV/HDV national prevalence. This study therefore sought describe the national geographic distribution of viral hepatitis infections and of HBV/HIV and HBV/HDV co-infections , and to produce a molecular characterization of these viruses among CAR's general population.

90

91 Methodology

92 *Study strategy and sample size*

93 This is a non-interventional descriptive (retrospective) study based on Dried Blood Spot (DBS) 94 samples obtained as part of the 4th Multiple Indicator Cluster Survey (MICS4) in the Central African 95 Republic (CAR) in 2010, carried out as part of the United Nations Children's Fund (UNICEF) 96 program to estimate the prevalence of HIV infection in the country's general population. Out of the 97 12,599 persons enrolled during this MICS4, 10,621 DBS samples were obtained and stored at -20°C.

98 The sample size for our study was calculated based on the previously reported prevalence of HBsAg 99 (10.6%) [11], a precision of 3% with a 95% confidence interval. From the 10,621 DBS, due to 100 insufficient amounts of some samples, only 9,378 were exploitable, covering all 14 prefectures and 101 Bangui, CAR's capital city. Samples from two prefectures (Nana-Gribizi and Ouham-Pende) were lost 102 during the storage of DBS. Of the 9,378 exploitable DBS, 413 tested HIV-positive, with 8,965 HIV-

negative. Among the 8,965 HIV-negative samples, a random selection was performed to include 4,467
samples in this study, to which we added 413 HIV-positive samples. We used all HIV positive samples
to determine HIV/hepatitis co-infection prevalence.

106

107 Socio-demographic data

Socio-demographic data were obtained from the Central African Institute of Statistics, Economic and Social Studies (ICASEES), which collected and archived all data related to each sample, including sex, age, ethnicity, educational level, marital status, residential area (region and urban or rural setting). All data were anonymized before processing the analyses. These data were collected from the standard questionnaire of the survey (www.childinfo.org), adapted to the context of Central African Republic.

113

114 Serological tests

115 Serological tests for hepatitis B, D and C viruses were carried out using the ELISA (enzyme-linked 116 immunosorbent assay) technique on Dried Blood Spot (DBS) stored at the Biological Resources 117 Centre at the Institut Pasteur de Bangui. These samples were made available to the team as soon as the 118 ethical approval was obtained in February 2012. The serological tests began on 8 May 2013. The HBV 119 markers HBsAg, anti-HBc (total), and anti-HBc (IgM) were tested using Abbott-Murex version 3 120 (Abbott-Murex Biotech Ltd, Dartford, Kent, UK) for the respective markers. Anti-HDV antibody was 121 tested using the DiaSorin kit for HDV, and Anti-HCV antibody (HCV-Ab) using the Murex anti-HCV 122 kit (DiaSorin, DiaSorin S. P.A. UK Branch Central Road). Serological tests were performed and 123 interpreted according to the manufacturer's recommendations.

- 124
- 125

Nucleic Acid Extraction and PCR amplification

126 Viral nucleic acids (DNA/RNA) were extracted with the Qiagen Kits (QIAamp DNA Blood Mini Kit 127 250 and QIA amp Viral RNA Mini Kit 50) according to the manufacturer's procedures. Subsequently, 128 the PreSl region of the HBV amplified using primer P1 (5'was а pair

129 TCACCATATTCTTGGGAACAAGA-3') /P2 (5'-TTCCTGAACTGGGAGCCACCA-3') with an 130 expected PCR product of 479 bp. For HIV, a nested RT-PCR was used to amplify the protease region 131 of the pol gene using two pairs of primers: PRIn1 (5'-TTT-TTT-AGG-GAA-AAT-TTG-3') /PRIn2 132 (5'-ATT-TTC-AGG-CCC-AAT-TTT-TGT-3') and PRIn3 (5'-CAG-ACC-AGA-GCC-AAC-AGC-133 3')/PRIn4 (5'-TCT-TCT-GTC-AAT-GGC-CAT-TGT-3) for primary PCR and nested PCR 134 respectively according to the ANRS protocol (http://www.hivfrench resistance.org). The R0 region of HDV was amplified with the primers Casey sens (5'CATGCCGACCCGAAGAGGAAAG3') and anti-135 136 sens (5'GAAGGAAGGCCCTCGAGAACAAGA3'), according to the previously published method 137 [16].

138

139 Sequencing

140 The PCR products were first purified using the Oiagen kit (OIAquick PCR Purification kit, 141 www.qiagen.com/handbooks.), then sent to GATC (Germany) for sequencing using the Sanger 142 method.

143

144 Sequences analysis

145 The chromatograms of the sequences obtained were cleaned and analyzed in CLC genomic workbench 146 V.8. The HIV subtypes were determined online, using the Stanford University website (HIV DRUG 147 RESISTANCE DATABASE, http://www.sierra2.stanford.edu). For HBV and HCV, the sequences 148 were aligned and compared with the reference sequences downloaded from the database (Genbank), 149 and construction of the phylogenetic trees was carried out using MEGA X software. 150 All sequences obtained were submitted to NCBI and were given the following accession number: *HBV*

(MT155997- MT156072), HDV (MT028414- MT028419), and HIV (MT121102- MT121107).

152

151

153 Statistical analysis

154 Data were analyzed using STATA Software.14. Percentages with a 95% confidence interval (CI) were 155 calculated. HBV-positive and HBV-negative groups were compared using χ^2 test or Fisher's exact test 156 for dichotomous variables and Student's t-test or Wilcoxon rank-sum test for continuous variables. 157 All variables associated with HBV in univariate analysis (p < 0.25) were then included in a backward

158 stepwise logistic regression. A *p*-value ≤ 0.05 was considered statistically significant.

159

Ethical considerations

161

160

Because this study was based partly on retrospective data linked to the fourth Multiple Indicator Cluster Survey (MICS-4) carried out in 2010, which was coupled with HIV screening in the general population, the introduction of a new consent form for participants was neither necessary, recommended or indeed possible.

166 The protocol anonymised the socio-demographic data stored at the «Institut Centrafricain des 167 Statistiques, des Études Économiques et Sociales (ICASEES) » and participants' blood samples, dried 168 blood spot (DBS), stored at the Biological Resource Centre of the Institut Pasteur de Bangui. The 169 detection of HIV infection during this survey is based on the anonymous-linked protocol developed by 170 the international DHS (Demographic and Health Surveys) programme and approved by the ICF Macro 171 Ethics Committee. According to this protocol, no name or other individual or geographical 172 characteristic that could identify an individual was linked to a blood sample. The standard MICS-4 173 questionnaire used (www.childinfo.org) was adapted to the context of the Central African Republic. The "Comité Scientifique chargé de Validation des Protocoles et des Résultats de Recherche en Santé 174 175 (CSVPRS)" of the Faculty of Health Sciences of the University of Bangui (Central African Republic), 176 which acts as the Central African Republic's national ethics committee, also approved the specific 177 anonymous-linked protocol for the MICS-4 survey under number 2/UB/FACSS/CSVPRS/10. The tests 178 used to detect HIV infection were strictly anonymous, and it was not possible to inform those tested of 179 the results of their examination. However, at the time of the MICS-4, whether or not they had agreed 180 to be tested for HIV, eligible persons (those providing their consent to be included in the survey)

received a coupon to obtain, if they so wished, advice and a free HIV test at a "Centre de Prévention et
de Dépistage Volontaire (CPDV)".

183 The protocol for this study was also assessed by the CSVPRS, which issued a favorable ethical 184 approval under number 6/UB/FACSS/CSVPRS/12. In the protocol submitted to the CSVPRS, we 185 noted the impossibility of collecting informed consent from participants due to the retrospective nature 186 of the study, which used DBS samples stored at the Biological Resources Centre of the Institut Pasteur 187 de Bangui, and the sociodemographic data being anonymous at the outset. We explained that there was 188 no possibility of contacting participants in order to obtain their consent again. The socio-demographic 189 data used to analyse the results of the study were obtained from the ICASEES, which collected and 190 archived all these data in relation to each DBS sample. An anonymous number was used to link the 191 biological results to the individual data, but conserved anonymity, again making it impossible to 192 contact participants to obtain their consent.

193

- 194 *Results*
- 195

Population characteristics

Among the 4,317 samples analyzed, 2,297 were from males (53.2%) and 2020 from females (46.8%) with a sex ratio of 1.13. The majority of subjects had either primary school or no education (44.8% and 33.4% respectively). More than half of the participants (2356/4317 or 54.6%) identified themselves as of the Protestant religion. The economic quintiles were second (25.0%), poor (22.7%) and medium (22.7%).

202

Prevalence of HBV, HCV, HBV/HIV, and HBV/HDV co-infections

Positive HBsAg and HBc-Ab were found in 555 subjects (12.9%), and 849 (19.7%), respectively. The
overall prevalence of anti-HCV was 0.65%. Co-infection of HBV/HIV was found in 49 subjects
(1.4%) of 3477 HBV tested population, and HBV/HDV co-infection was found in 92 subjects (16.6%)

- 206 of the HBV infected population. The prevalence of different hepatitis viral markers and HBV/HIV and
- 207 HBV/HDV associated with socio-demographic data are reported in *Table 1*.

Table 1. Prevalence and distribution of HBsAg, HBc Ab, HCV, HBsAg/HIV and, HBsAg/HDV coinfections

Characteristics	Number	Percentage	Coinfection H	IV/HBs	Ag	HBs	Ag		HBc an	tibody		HCV and	tibody	1	HDV*	antibod	у
		-	Positive (n)	%	Р	Positive (n)	%	Р	Positive (n)	%	Р	Positive (n)	%	Р	Positive (n)	%	Р
Gobal prevalence	4317	100	49(3477)	1.4		555(4317)	12.9		849(4317)	19.7		28(4317)	0.6		92(555)	16.6	
Sex																	
Male	2297	53.2	32(1858)	1.7	0.107	280	12.2	0.163	443	20.1	0.503	14(2297)	0.6	0.733	53(280)	18.9	0.133
Female	2020	46.8	17(1589)	1.1		275	13.6		406	19.3		14(2020)	0.7		39(275)	14.2	
Age (years)																	
0 to 25	1075	24.9	13(846)	1.5		147(1075)	13.8		226(1075)	21.0		3(1075)	0.3		24(147)	16.3	
26 to 35	1236	28.6	10(986)	1.0	0 454	161(1236)	13.0	0 606	254(1236)	20.6	0.271	7(1236)	0.6	0.012	24(161)	14.9	0.525
36 to 45	961	22.3	10(766)	1.3	0.454 3	122(961)	12.7	0.696	177(961)	18.4	0.271	4(961)	0.4	0.012	18(122)	14.7	0.020
> 45	1045	24.2	16(849)	1.9		125(1045)	12.0		192(1045)	18.4		14(1045)	1.3		26(125)	20.8	
School level																	
No school	1442	33.4	13(1150)	1.1		184(1442)	12.8		282(1442)	19.6		14(1442)	1.0		32(184)	17.4	
Preschool	2	0.1	0(1)	0.0		0(2)	0.0		0(2)	0.0		0(2)	0.0		0(0)	0.0	
Primary	1934	44.8	20(1554)	20.0	0.194	259(1934)	13.4	0.822	396(1934)	20.5	0.629	12(1934)	0.6	0.268	47(259)	2.4	0.456
Secondary and High	848	19.6	13(670)	1.9		101(848)	11.9		155(848)	18.3		2(848)	0.2		12(101)	11.8	
University	91	2.1	3(72)	4.8		11(91)	12.1		16(91)	17.6		0(91)	0.0		1(11)	9.1	
**Economic quintile																	
Poor	979	22.7	10(786)	1.3	0.001	141(979)	14.4	0.155	217(979)	22.2	0.033	8(979)	0.8	0.840	25(141)	17.7	0.438

Second	1079	25.0	9(874)	1.0	134(1079)	12.4	221(1079)	20.5	6(1079)	0.6	20(134) 4	1.9
Medium	978	22.6	7(785)	0.9	119(978)	12.2	187(978)	19.1	7(978)	0.7	19(119) 10	6.0
Fourth	745	17.3	8(595)	1.3	82(745)	11.0	120(745)	16.1	3(745)	0.4	10(82) 12	2.2
Richer	536	12.4	15(407)	3.7	79(536)	14.7	104(536)	19.4	4(536)	0.7	18(79) 22	2.8
Religion												
Animist, Buddhist, other	69	1.60	2(55)	3.6	10(69)	14.5	15(69)	21.7	0(69)	0.0	2(10) 20	0.0
Catholic	1344	31.1	8(1081)	0.7	164(1344)	12.2	256(1344)	19.0	9(1344)	0.7	30(164) 18	8.3
Muslim	514	11.9	10(402)	2.5 (0.053 74(514)	14.4 0.77	72 117(514)	22.8 0.290	2(514)	0.4 0.84	42 18(74) 24	4.3 0.195
Atheist	34	0.8	0(27)	0.0	4(34)	11.7	9(34)	26.5	0(34)	0.0	0(4)	0.0
Protestant	2356	54.6	29(1882)	1.5	303(2356)	12.9	452(2356)	19.2	17(2356)	0.7	42(303) 13	3.9

211 (*) : Analysis of HDV in 555 positive AgHBs

212 (**) : The Economic quintile is the economic world bank classification.

217

218 No difference of HBV infection was observed between age groups (p=0.70), but for HCV infection, a 219 significant difference was observed for subjects older than 45 years (p=0.012). Among districts the prevalence of the four viruses varied (Table 2). Even among districts with the lowest blood samples 220 221 collection.. Vakaga reported the highest prevalence of HBsAg (33.3%), followed by Bamingui-222 Bangoran (19.5%) and Ouaka (16.9%). However, in Lobaye and Mambere-Kadéi, HBV prevalence 223 was 8.9% and 8.1% respectively. The global prevalence of HBV/HIV co-infection was 1.41%, with 224 the highest prevalence among Bangui samples (5.1%), followed by Haut-Mbomou (3.7%) and Haute-225 Kotto (3.4%). 226 For ethnic groups, prevalence of HBsAg (41.7%; p < 0.001) and of anti-HBc antibody (57.1%; p < 0.001) 227 0.001) was higher among "non identified ethnic groups", followed by the Banda ethnic group (15.1% 228 and 24.2%), respectively). In contrast, prevalence of HBV/HIV co-infection was slightly higher in the

Hausa ethnic group, followed by the Zande/Nzakara ethnic group. Analyses of factors associated witheach infection are shown *in Table 3*.

Table 2. Geographical distribution of hepatitis (B, C and D) viruses

Geographical distribution	Percentag Number e		Coinfection H	lIV/HBs/	Ag	HE	₿sAg		HBc A	ntibody		HCV Ar	itibody	1	HDV An	tibody*	
		-	Positive (n)	%	Р	Positive (n)	%	Р	Positive (n)	%	Р	Positive (n)	%	Р	Positive (n)	%	Р
Residence/Prefecture																	
Rural	2704	62.6	20(2192)	0.9	0.001	365(2704)	13.5	0.103	610(2704)	22.6	0.001	13(2704)	0.5	0.075	58(365)	15.9	0.547
Urban	1613	37.4	29(1255)	2.3	0.001	190(1613)	11.8	0.105	239(1613)	14.8	0.001	15(1613)	0.9	0.075	34(190)	17.9	0.547
Prefecture																	
Bamingui Bangoran	246	5.7	1(189)	0.5		48(246)	19.5		103(246)	41.9		5(246)	2.0		10(48)	20.8	
Bangui (City of) **	341	7.9	13(254)	5.1		51(341)	15.0		74(341)	21.7		2(341)	0.6		8(51)	15.7	
Basse Kotto	287	6.6	1(247)	0.4		31(287)	10.8		55(287)	19.2		6(287)	2.1		3(31)	9.7	
Haut Mbomou	259	6.0	7(191)	3.7		39(259)	15.1		49(259)	18.9		1(259)	0.4		5(39)	12.8	
Haute Kotto	277	6.4	7(208)	3.4		39(277)	14.1		49(277)	17.7		1(277)	0.4		5(39)	12.8	
Kemo	379	8.8	3(307)	1.0		59(379)	15.6		74(379)	19.5		3(379)	0.8		11(59)	18.6	
Lobaye	281	6.5	0(245)	0.0	0.001	25(281)	8.9	0.001	28(281)	10.0	0.001	2(281)	0.7	0.031	7(25)	28.0	0.150
Mambere Kadei	335	7.8	0(271)	0.0		27(335)	8.1		73(335)	21.8		0(335)	0.0		9(27)	33.3	
Mbomou	307	7.1	4(246)	1.6		42(307)	13.7		50(307)	16.3		0(307)	0.0		4(42)	9.5	
Nana Mambere	335	7.8	2(259)	0.8		37(335)	11.0		39(335)	11.6		1(335)	0.3		4(37)	10.8	
Ombella Mpoko	348	8.1	2(271)	0.7		35(348)	10.1		77(348)	22.1		0(348)	0.0		5(35)	14.3	
Ouaka	279	6.5	3(219)	1.4		47(279)	16.8		92(279)	33.0		2(279)	0.7		7(47)	14.9	
Ouham	291	6.7	2(256)	0.8		32(291)	11.0		39(291)	13.4		3(291)	1.0		4(32)	12.5	

Sangha Mbaere	325	7.5	4(266)	1.5	34(325)	10.5	34(325)	10.5	2(325)	0.6	10(34)	29.4	
Vakaga	27	0.6	0(18)	0.0	9(27)	33.3	13(27)	48.1	0(27)	0.0	0(9)	0.0	
Ethnicity													
NIEG(1)	348	8.1	4(262)	1.6	51(348)	41.1	82(348)	57.0	4(348)	1.2	11(51)	25.6	
Banda	1183	27.4	12(927)	1.3	179(1183)	15.1	286(1183)	24.2	11(1183)	0.9	31(179)	17.3	
Gbaya	1074	24.9	11(880)	1.2	110(1074)	10.2	174(1074)	16.2	6)1074)	0.6	20(110)	18.2	
Haoussa	238	5.5	5(188)	2.7	32(238)	13.4	50(238)	21.0	2(238)	0.8	7(32)	21.9	
Mandja	364	8.4	4(288)	1.4	54(364) 0.739	14.8	75(364) 0.001	20.6	1(364) 0.001	0.3	4(54)	7.4	0.360
Mboum	60	1.4	1(52)	1.9	2(60)	3.3	3(60)	5.0	0(60)	0.0	1(2)	50.0	0.300
Ngbaka/Bati	326	7.5	3(274)	1.1	39(326)	12.0	47(326)	14.4	2(326)	0.6	6(39)	15.4	
Sara	149	3.4	0(123)	0.0	16(149)	10.7	29(149)	19.5	0(149)	0.0	2(16)	12.5	
Yakoma/Sango	257	5.9	3(215)	1.4	22(257)	8.6	39(257)	15.2	2(257)	0.8	4(22)	18.2	
Zande/Nzakara	318	7.4	6(238)	2.5	50(318)	1.7	64(318)	20.1	0(318)	0.0	6(50)	12.0	

234 (*) : Analysis of HDV in 555 positive AgHBs

235 (**) : City of Bangui : Bangui is the capital of Central African Republic

236 (1) : Non identified ethnic groups

- 237
- 238
- Figure 1: Circulation of viruses and their genotypes in CAR. All four viruses were present in the southeastern part of the Country. Bangui, the capital
- 240 city, is affected by all three viruses and the circulation of the two genotypes (D and E) of HBV.

241 Associated risk factors for HIV-HBV co-infection

242 In our multivariate analysis, being wealthier (OR 4.25, 95% CI: 1.71-10.51) and living in an urban

- 243 area (OR 2.56, 95% CI: 1.44 - 4.56), more specifically Bangui and Vakaga (OR 10.14, 95% CI 1.31-
- 244 78.21), were associated with HIV/HBV co-infection (Table 3).
- 245
- 246 Table 3. Association between HBV/HIV coinfection and risk factors.

247

248

Caractéristiques	Co-i	nfection	HIV/HBV	
	OR	р	IC(95%)	
**Economic quintile				
Wealthier	4.25	0.002	[1.71 - 10.5	1]
Residence/Prefecture				
Urban	2.56	0.001	[1.44 - 4.5	6]
Prefecture				
Bangui (City of) **	10.14	0.026	[1.31 - 18.2	1]
Vakaga				
Molecular	chara	cterizat	tion of HBV	, HDV, and HIV isolates
A total of 77 HBV	⁷ strain	ns base	d on the Pr	eS1 region were sequenced. Of these 77 strains, 6 w
HBV/HDV co-inf	ected	and 6	strains wer	e HBV/HIV co-infected. Of the 77 HBV isolates,
strains (93.5%) be	longed	l to gen	otype E, an	d 5 isolates (6.5%) to genotype D (Figure 2). Of the
UDV positivo som	nlag 6	Compl	og word gud	assistilly sequenced and all belonged to alade 1 (Fig

- 257 HDV positive samples, 6 samples were successfully sequenced and all belonged to clade 1 (Figure
- 258 3).
- 259

260 Figure 2: Phylogenetic analyses of 77 HBV isolates. The tree was constructed in MEGA using the 261 Neighbor-joining statistical method, the Kimura-2 parameter model, and the bootstrap method of 262 1000 replicates. The black cercles represent reference sequence genotypes A-H downloaded from 263 the database. The remaining are HBV sequences discussed in the present study, and the two 264 genotypes (E and D) are mentioned on the tree.

265

266 Figure 3: Phylogenetic analyses of the 6 HDV isolates. The tree was constructed in MEGA using 267 the Neighbor-joining statistical method, the Kimura-2 parameter model, and the bootstrap method 268 of 1000 replicates. The black cercles represent the HDV sequences discus by the present study, and 269 the remaining are the reference sequences with the country's names.

270

278

271 Table 4 presents the 6 sequences of HIV and their GenBank accession number. After similarity 272 analysis via the NCBI database and the Stanford University website sub-types-1 (A1 and G), 4 273 recombinants of sub-type-1 were identified.

274
Table 4. Different subtypes of HIV-1 isolate

	Laboratory ID/ GenBank Accession Number	Sub-types	Similarity (%)
	CARVIHBG280/MT121104	CRF01_AE	100
	CARVIHVK022/MT121105	A1	100
	CARVIHSM173/MT121107	G	94.6
	CARVIHSM651/MT121102	CRF02_AG	100
	CARVIHKE584/ MT121103	CRF12_BF	100
	CAVIHHK175/ MT121106	CRF11_cpx	100
275			
276			
277	Discussion		
278			

The study reported the prevalence of viral hepatitis B, C and Delta biomarkers and the molecular characterization of HBV, HDV, HCV and HIV/Hepatitis coinfection of DBS from a nationwide investigation in the CAR.

282 In all our analyzed cohorts, HBsAg was highly endemic, but its prevalence varied widely among 283 different regions of the CAR, ranging from 8.1% in Mambere Kadéi to 33.3% in Vakaga. Although 284 it is difficult to compare different age groups, HBsAg prevalence was similar in children and adults: 285 0 to 25 years (13.7%), 25 to 35 years (13.0%), 36 to 45 years (12.7%), and > 45 years (12.0%). 286 These results resemble those of a previous study showing constancy in HBV prevalence among all 287 age groups in the CAR [17]. This finding may indicate a high burden and an excessive risk of early 288 infection with HBV in children, resulting in a high HDV prevalence (16.6%), which has a similar 289 distribution for HBV across all age groups. Previous studies have designated the CAR as an 290 endemic region for HBV and HDV co-infection [11,15,18,19].

291 The seroprevalence of HBV and HIV co-infection was 1.4%, demonstrating that the CAR is an292 endemic region for this co-infection.

293 In this study, the prevalence of HBc antibody was 19.7%. The distribution of this prevalence 294 follows HBsAg prevalence. The presence of these antibodies indicates that a high proportion of the 295 population had been exposed to HBV. That prevalence is high in rural areas (22.6%; p=0.001), 296 among the economically poor (22.7%), in the Vakaga and Bamingui Bangoran regions (48.11 % 297 and 41.9% respectively; p<0.001), and among other ethnic groups as well as the Banda group (57.1 298 and 24.2%; p<0.001). Compared to previous studies in CAR, this prevalence has significantly 299 decreased, halving since 2010 when it was 42.3% [31], declining to 27.1% in rural communities in 2013 [11], and to 26.7% among students and 21.4% among pregnant women in 2018 [15]. This 300 301 reduction may be explained by the intensification of hepatitis B surveillance measures in blood 302 transfusion and the introduction of hepatitis B vaccination in the Expanded Program of 303 Immunisation in CAR in 2008.

304 Although HCV treatment has not been yet initiated in CAR, HCV prevalence in this study was very 305 low (0.65%). Our finding contrasts with a previous review estimating HCV prevalence in Sub-306 Saharan Africa between 2000 and 2013, which showed West and Central Africa with the highest 307 HCV prevalence [21]. In our study, HCV prevalence in the Bangui samples was 0.59%. We found a 308 higher prevalence in Bamingui-Bangoran samples (2.03%), with variability across regions and no 309 cases at all among Vakaga samples (Table 2). The Bamingui-Bangoran and Vakaga prefectures are 310 in close proximity, but Vakaga is the most sparsely populated prefecture in the CAR, where very 311 few blood samples were collected compared to other prefectures. We would suggest, then, that 312 socio-demographic and economic factors of these prefectoral populations may account for the 313 differential prevalence of these neighboring regions affecting the prevalence of these viruses.

In addition, the prevalence of anti-HCV was lower in the 0 to 25 age group and higher in those over 45 years old. Similar results have been reported in CAR, Cameroon and Gabon, where massive iatrogenic transmission during medical campaigns through improperly sterilized syringes, needles and the transfusion of contaminated blood products may explain the high prevalence among elderly subjects rather than continuous exposure [32, 33].

The main risk factors of HBV identified in our study were economic quintile, religion, residence,prefecture, and ethnicity.

From this study, 77 isolates of HBV were sequenced and genotyped. HBV was categorized into eight genotypes from A to H, based on a divergence of more than 8% in the entire nucleotide sequence of the viral DNA. Two additional genotypes I and J were recently proposed [22]. In the CAR, however, evidence of only three of these HBV genotypes (A, D and E) were reported in previous studies [15,18,23,24].

The present study identified two HBV genotypes (D and E), with HBV genotype E accounting for the dominant strains circulating throughout the CAR (figure 1). This finding conforms with previous studies identifying HBV genotypes E as the most dominant strains circulating in West and Central Africa [18,25]. This HBV genotype has very low diversity and emerged recently, just 200

years or less [25]. HBV genotype D has already been previously described in a Bangui patient with
chronic hepatitis [18]. This genotype is predominant in the Maghreb [26], and its low representation
in CAR suggests that it may be imported by population and trade movements with other countries in
North, West, and Central Africa.

HDV clades (1 to 8) varied across geographic regions [27]. From the present study, all 6 isolates belong to clade 1, in accordance with a previous study [28]. The HDV clade 1 has been reported to have rapid and aggressive HDV virion formation and dissemination, making patients infected with this type suffering more adverse outcomes and decreased chances of survival. This finding requires further study of liver disease patients in the CAR.

Among the 6 isolates of HIV co-infected with HBV in this study, circulating recombinant forms

CRF (CRF01_AE, CRF02_AG, CRF12_BF) and the CRF11_cpx complex were identified. These isolates have already been described as part of the pandemic subtypes in Africa [28,29]. In the CAR, the CRF11_cpx complex has been described as predominant. It is associated with antiretroviral resistance, followed by the A1 type [30].

Our study has certain limitations that should be considered, notably the absence of co-infection
HIV/HCV, triple infection HB/HCV/HDV or HIV/HBV/HCV, and multiple infection
HIV/HBV/HCV/HDV, as well as the absence of detection of HCV-RNA sequences. Additionally,
the study did not include an assessment of liver function.

348

349 Conclusion

This study provides a national prevalence and geographical distribution of hepatitis viruses in the CAR, and it shows that hepatitis viral infections remain a serious public health problem in the country. HBV and HDV remain highly prevalent. HBV prevalence was distributed equally across age groups, and genotype E remains dominant. Our results assume? Suggest? that high prevalence of HBV and HBV/HDV co-infection continue to be responsible for morbidity and mortality, despite the introduction of HBV vaccination in 2008. The data and analysis from this study will be useful in

assisting authorities to implement measures to limit HBV, HDV, HCV, and HIV infections andcoinfection in the CAR.

358

359 Acknowledgment: We thank the «Institut Centrafricain des Statistiques et des Etudes
360 Economiques et Sociales – ICASEES for providing us with the statistical data for this study.

361

362 **Funding:** No fundings

363

364 Competing interest: The authors declare that they have no competing interest

365

- 366 Authors' contributions
- 367 Conceptualization: Narcisse Patrice Joseph Komas, Muriel Vray, Alexandre Manirakiza, Sandrine
 368 Moussa, Claudine Bekondi
- 369 Data curation: Narcisse Patrice Joseph Komas, Parvine Basimane-Bisimwa, Brice Martial
- 370 Yambiyo, Alexandre Manirakiza
- 371 Formal analysis: Parvine Basimane-Bisimwa, Giscard Koyaweda, Brice Martial Yambiyo,
- 372 Alexandre Manirakiza, Benjamin Seydou Sombié, Ulrich Vickos, Narcisse Patrice Joseph Komas
- 373 Investigation: Parvine Basimane-Bisimwa, Giscard Koyaweda, Edgarthe Ngaïganam, Ornella
- 374 Anne Demi Sibiro,
- 375 Methodology: Parvine Basimane-Bisimwa, Giscard Koyaweda, Muriel Vray, Narcisse Patrice
- 376 Joseph Komas
- 377 **Project Administration :** Narcisse Patrice Joseph Komas,
- 378 Resources: Sandrine Moussa, Pulchérie Pélembi, Narcisse Patrice Joseph Komas
- **Supervision:** Narcisse Patrice Joseph Komas
- 380 Writing original draft: Parvine Basimane-Bisimwa, Giscard Koyaweda, Narcisse Patrice Jospeh

381 Komas

382 Writing – review & editing: Parvine Basimane-Bisimwa, Giscard Wilfried Koyaweda, Ulrich

383 Vickos, Tamara Giles-Vernick, Alexandre Manirakiza, Muriel Vray, Narcisse Patrice Komas384

385 References

- 386 [1] Valenzuela P. Hepatitis A, B, C, D and E viruses: Structure of their genomes and general
 387 properties. Gastroenterol Jpn 1990;25:62–71. doi:10.1007/BF02779931.
- Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral
 hepatitis and preventive strategies. World J Clin Cases 2018;6:589–99.
 doi:10.12998/wjcc.v6.i13.589.
- 391 [3] Papastergiou V, Lombardi R, MacDonald D, Tsochatzis EA. Global epidemiology of
 392 hepatitis B virus (HBV) infection. Curr Hepat Rep 2015;14:171–8. doi:10.1007/s11901-015393 0269-3.
- WHO. World Health Organization. Global Hepatitis Report. 2017a. Glob Hepat Program
 Dep HIV/AIDS 2017;Disponível:14.
- Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus
 infection: New estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine
 2012;30:2212–9. doi:10.1016/j.vaccine.2011.12.116.
- 399 [6] Hepatitis D n.d. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d (accessed June
 400 19, 2020).
- 401 [7] Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it
 402 differ from hepatitis B monoinfection? Saudi J Gastroenterol 2012;18:18–22.
 403 doi:10.4103/1319-3767.91731.
- 404 [8] Puigvehí M, Moctezuma-Velázquez C, Villanueva A, Llovet JM. The oncogenic role of
 405 hepatitis delta virus in hepatocellular carcinoma. JHEP Reports 2019;1:120–30.
 406 doi:https://doi.org/10.1016/j.jhepr.2019.05.001.
- 407 [9] Abbas Z, Abbas M, Abbas S, Shazi L. Hepatitis D and hepatocellular carcinoma. World J

408 Hepatol 2015;7:777–86. doi:10.4254/wjh.v7.i5.777.

- 409 [10] Hoffmann CJ TC. Clinical implications of HIV and hepatitis B co-infection in Asia and
 410 Africa. Lancet Infect Dis 2007:402–409.jour
- 411 [11] Stockdale AJ, Chaponda M, Beloukas A, Phillips RO, Matthews PC, Papadimitropoulos A,
- et al. Prevalence of hepatitis D virus infection in sub-Saharan Africa: a systematic review
 and meta-analysis. Lancet Glob Heal 2017;5:e992–1003. doi:10.1016/S2214109X(17)30298-X.
- 415 [12] Komas NP, Vickos U, Hübschen JM, Béré A, Manirakiza A, Muller CP, et al. Cross416 sectional study of hepatitis B virus infection in rural communities, Central African Republic.
 417 BMC Infect Dis 2013;13:286. doi:10.1186/1471-2334-13-286.
- 418 [13] Crovari P, Santolini M, Bandettini R, Bonanni P, Branca P, Coppola RC. Epidemiology of
 419 HBV and HDV infections in a rural area of Central African Republic. Prog Clin Biol Res
 420 1991;364:69–73.
- [14] Classement des États du monde par prévalence du VIH (% population âgée de 15 à 49 ans)
 n.d.https://atlasocio.com/classements/sante/maladies/classement-etats-par-prevalence-vih-

423 pourcentage-monde.php#google_vignette (accessed January 18, 2021).

- 424 [15] Komas NP, Ghosh S, Abdou-Chekaraou M, Pradat P, Al Hawajri N, Manirakiza A, et al.
 425 Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five
 426 years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young
 427 adults. PLoS Negl Trop Dis 2018;12:e0006377. doi:10.1371/journal.pntd.0006377.
- Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis delta
 virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol
 2001;82:2709–18. doi:10.1099/0022-1317-82-11-2709.
- 431 [17] Andernach IE, Leiss L V., Tarnagda ZS, Tahita MC, Otegbayo JA, Forbi JC, et al.
 432 Characterization of hepatitis delta virus in sub-Saharan Africa. J Clin Microbiol
 433 2014;52:1629–36. doi:10.1128/JCM.02297-13.

- 434 [18] Bekondi C, Olinger CM, Boua N, Talarmin A, Muller CP, Le Faou A, et al. Central African
- 435 Republic is part of the West-African hepatitis B virus genotype E crescent. J Clin Virol
 436 2007;40:31–7. doi:10.1016/j.jcv.2007.05.009.
- 437 [19] Bekondi C. Aspects cliniques et epidemiologiques des infections a virus de l'hepatite b en
 438 republique centrafricaine. Université Henri Poincaré Nancy 1, 2007. doi:2008NAN10129.
- 439 [20] Bertoletti A, Hong M. Age-Dependent Immune Events during HBV Infection from Birth to
 440 Adulthood: An Alternative Interpretation. Front Immunol 2014;5:441.
 441 doi:10.3389/fimmu.2014.00441.
- 442 [21] Mora N, Adams WH, Kliethermes S, Dugas L, Balasubramanian N, Sandhu J, et al. A
 443 Synthesis of Hepatitis C prevalence estimates in Sub-Saharan Africa: 2000-2013. BMC
 444 Infect Dis 2016;16:1–8. doi:10.1186/s12879-016-1584-1.
- 445 [22] Lin CL KJ. The clinical implications of hepatitis B virus genotype: recent advances. J
 446 Gastroenterol Hepatol 2011;26:123–130.
- 447 [23] Toxoplasmosis of Animals and Man. By J. P. Dubey and C. P. Beattie. 220 pages. ISBN 0
 448 8493 4618 5. CRC Press, Boca Raton, 1988. £108.00. Parasitology 1990;100:500–1.
 449 doi:10.1017/s0031182000078914.
- [24] Koyaweda Giscard Wilfried, Rose J, Machuka E, Juma J, Macharia R, Patrice N, et al.
 Detection of circulating hepatitis B virus immune escape and polymerase mutants among
 HBV-positive patients attending Institut Pasteur de Bangui, Central African Republic. Int J
 Infect Dis 2020;90:138–44. doi:10.1016/j.ijid.2019.10.039.
- 454 [25] Kramvis A. Genotypes and genetic Variability of Hepatitis B virus. Intervirology
 455 2014;57:141–50. doi:10.1159/000360947.
- 456 [26] Forbi JC, Ben-Ayed Y, Xia GL, Vaughan G, Drobeniuc J, Switzer WM KY. Disparate
 457 distribution of hepatitis B virus genotypes in four sub-Saharan African countries. J Clin Virol
 458 2013;1:59–66. doi:doi: 10.1016/j.jcv.2013.06.028.
- 459 [27] Le Gal F, Gault E, Ripault MP, Serpaggi J, Trinchet JC, Gordien E, et al. Eighth major clade

460 for hepatitis delta virus. Emerg Infect Dis 2006;12:1447–50. doi:10.3201/eid1209.060112.

- 461 [28] Brennan CA, Bodelle P, Coffey R, Devare SG, Golden A, Hackett J, et al. The Prevalence of
 462 Diverse HIV-1 Strains Was Stable in Cameroonian Blood Donors From 1996 to 2004
 463 2008;49:432–9.
- 464 [29] Ndembi N, Takehisa J, Zekeng L, Kobayashi E. Genetic Diversity of HIV Type 1 in Rural
 465 Eastern Cameroon 2004;37:1641–50.
- 466 [30] Moussa S, Pinson P, Pelembi P, Gody J-C, Mbitikon O, Fikouma V, et al. First data on HIV467 1 resistance mutations to antiretroviral drugs in Central African Republic. AIDS Res Hum
 468 Retroviruses 2010;26:1247–8. doi:10.1089/aid.2010.0091.
- 469 [31] Komas NP, Baï-Sepou S, Manirakiza A, Léal J, Béré A, Le Faou A. The prevalence of
 470 hepatitis B virus markers in a cohort of students in Bangui, Central African Republic. BMC
 471 Infect Dis. 2010;10:226. Published 2010 Jul 29. doi:10.1186/1471-2334-10-226.
- [32] Njouom, R., Frost, E., Deslandes, S., Mamadou-Yaya, F., Labbe, A. C., Pouillot, R., ... &
 Pepin, J. Predominance of hepatitis C virus genotype 4 infection and rapid transmission
 between 1935 and 1965 in the Central African Republic. Journal of general virology. 2009;
 90(10), 2452-2456.
- [33] Njouom, R., Pasquier, C., Ayouba, A., Gessain, A., Froment, A., Mfoupouendoun, J., ... &
 Nerrienet, E. High rate of hepatitis C virus infection and predominance of genotype 4 among
 elderly inhabitants of a remote village of the rain forest of South Cameroon. Journal of
 medical virology. 2003 ; 71(2), 219-225.
- 480
- 481
- 482

Map of different viruses and HBV genotypes by prefecture





Figure 1

Figure 1




0.020

Figure 2

1

Figure 2



1

0.050

Figure 3

Figure 3